1. Waddington, C.H. The epigenotype.Endeavour1, 18–20 (1942).

   Google Scholar 

2. Berger, S.L., Kouzarides, T., Shiekhattar, R. & Shilatifard, A. An operational definition of epigenetics.Genes Dev.23, 781–783 (2009).

   Google Scholar 

3. Esteller, M. Epigenetics in cancer.N. Engl. J. Med.358, 1148–1159 (2008).

   Google Scholar 

4. Jones, P.A. & Baylin, S.B. The epigenomics of cancer.Cell128, 683–692 (2007).

   Google Scholar 

5. Bird, A. DNA methylation patterns and epigenetic memory.Genes Dev.16, 6–21 (2002).

   Google Scholar 

6. Wang, Y. & Leung, F.C. An evaluation of new criteria for CpG islands in the human genome as gene markers.Bioinformatics20, 1170–1177 (2004).

   Google Scholar 

7. Suzuki, M.M. & Bird, A. DNA methylation landscapes: provocative insights from epigenomics.Nat. Rev. Genet.9, 465–476 (2008).

   Google Scholar 

8. Futscher, B.W. et al. Role for DNA methylation in the control of cell type specific maspin expression.Nat. Genet.31, 175–179 (2002).

   Google Scholar 

9. Hattori, N. et al. Epigenetic control of mouse Oct-4 gene expression in embryonic stem cells and trophoblast stem cells.J. Biol. Chem.279, 17063–17069 (2004).

   Google Scholar 

10. Doi, A. et al. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts.Nat. Genet.41, 1350–1353 (2009).

    Google Scholar 

11. Meissner, A. et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells.Nature454, 766–770 (2008).

    Google Scholar 

12. Lister, R. et al. Human DNA methylomes at base resolution show widespread epigenomic differences.Nature462, 315–322 (2009).

    Google Scholar 

13. Tahiliani, M. et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1.Science324, 930–935 (2009).

    Google Scholar 

14. Ito, S. et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification.Nature466, 1129–1133 (2010).

    Google Scholar 

15. Kouzarides, T. Chromatin modifications and their function.Cell128, 693–705 (2007).

    Google Scholar 

16. Allis, C.D. et al. New nomenclature for chromatin-modifying enzymes.Cell131, 633–636 (2007).

    Google Scholar 

17. Li, B., Carey, M. & Workman, J.L. The role of chromatin during transcription.Cell128, 707–719 (2007).

    Google Scholar 

18. Barski, A. et al. High-resolution profiling of histone methylations in the human genome.Cell129, 823–837 (2007).

    Google Scholar 

19. Rosenfeld, J.A. et al. Determination of enriched histone modifications in non-genic portions of the human genome.BMC Genomics10, 143 (2009).

    Google Scholar 

20. Mikkelsen, T.S. et al. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells.Nature448, 553–560 (2007).

    Google Scholar 

21. Esteller, M. Cancer epigenomics: DNA methylomes and histone-modification maps.Nat. Rev. Genet.8, 286–298 (2007).

    Google Scholar 

22. Feinberg, A.P. Cancer epigenetics is no Mickey Mouse.Cancer Cell8, 267–268 (2005).

    Google Scholar 

23. Jones, P.A. & Laird, P.W. Cancer epigenetics comes of age.Nat. Genet.21, 163–167 (1999).

    Google Scholar 

24. Irizarry, R.A. et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores.Nat. Genet.41, 178–186 (2009).

    Google Scholar 

25. Eden, A., Gaudet, F., Waghmare, A. & Jaenisch, R. Chromosomal instability and tumors promoted by DNA hypomethylation.Science300, 455 (2003).

    Google Scholar 

26. Howard, G., Eiges, R., Gaudet, F., Jaenisch, R. & Eden, A. Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice.Oncogene27, 404–408 (2008).

    Google Scholar 

27. Rodriguez, J. et al. Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers.Cancer Res.66, 8462–9468 (2006).

    Google Scholar 

28. Ogawa, O. et al. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour.Nature362, 749–751 (1993).

    Google Scholar 

29. Watt, P.M., Kumar, R. & Kees, U.R. Promoter demethylation accompanies reactivation of theHOX11 proto-oncogene in leukemia.Genes Chromosom. Cancer29, 371–377 (2000).

    Google Scholar 

30. Wilson, A.S., Power, B.E. & Molloy, P.L. DNA hypomethylation and human diseases.Biochim. Biophys. Acta1775, 138–162 (2007).

    Google Scholar 

31. Saito, Y. et al. Specific activation of microRNA-127 with downregulation of the proto-oncogeneBCL6 by chromatin-modifying drugs in human cancer cells.Cancer Cell9, 435–443 (2006).

    Google Scholar 

32. Huang, Y.W. et al. Epigenetic repression of microRNA-129–2 leads to overexpression ofSOX4 oncogene in endometrial cancer.Cancer Res.69, 9038–9046 (2009).

    Google Scholar 

33. Lujambio, A. et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells.Cancer Res.67, 1424–1429 (2007).

    Google Scholar 

34. Toyota, M. et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer.Cancer Res.68, 4123–4132 (2008).

    Google Scholar 

35. Ley, T.J. et al. DNMT3A Mutations in acute myeloid leukemia.N. Engl. J. Med.363, 2424–2333 (2010).

    Google Scholar 

36. Burmeister, T. et al. The MLL recombinome of adult CD10-negative B-cell precursor acute lymphoblastic leukemia: results from the GMALL study group.Blood113, 4011–4015 (2009).

    Google Scholar 

37. Meyer, C. et al. New insights to the MLL recombinome of acute leukemias.Leukemia23, 1490–1499 (2009).

    Google Scholar 

38. Delhommeau, F. et al. Mutation in TET2 in myeloid cancers.N. Engl. J. Med.360, 2289–2301 (2009).

    Google Scholar 

39. Ko, M. et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.Nature468, 839–843 (2010).

    Google Scholar 

40. Fraga, M.F. et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4is a common hallmark of human cancer.Nat. Genet.37, 391–400 (2005).

    Google Scholar 

41. Seligson, D.B. et al. Global histone modification patterns predict risk of prostate cancer recurrence.Nature435, 1262–1266 (2005).

    Google Scholar 

42. Chan, E.M. et al. MOZ and MOZ-CBP cooperate with NF-κB to activate transcription from NF-κB–dependent promoters.Exp. Hematol.35, 1782–1792 (2007).

    Google Scholar 

43. Yang, X.J. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases.Nucleic Acids Res.32, 959–976 (2004).

    Google Scholar 

44. Ferrari, R. et al. Epigenetic reprogramming by adenovirus e1a.Science321, 1086–1088 (2008).

    Google Scholar 

45. Rasti, M., Grand, R.J., Mymryk, J.S., Gallimore, P.H. & Turnell, A.S. Recruitment of CBP/p300, TATA-binding protein and S8 to distinct regions at the N terminus of adenovirus E1A.J. Virol.79, 5594–5605 (2005).

    Google Scholar 

46. Gayther, S.A. et al. Mutations truncating the EP300 acetylase in human cancers.Nat. Genet.24, 300–303 (2000).

    Google Scholar 

47. Gorrini, C. et al. Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response.Nature448, 1063–1067 (2007).

    Google Scholar 

48. Bolden, J.E., Peart, M.J. & Johnstone, R.W. Anticancer activities of histone deacetylase inhibitors.Nat. Rev. Drug Discov.5, 769–784 (2006).

    Google Scholar 

49. Ropero, S. et al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition.Nat. Genet.38, 566–569 (2006).

    Google Scholar 

50. Saunders, L.R. & Verdin, E. Sirtuins: critical regulators at the crossroads between cancer and aging.Oncogene26, 5489–5504 (2007).

    Google Scholar 

51. Pruitt, K. et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation.PLoS Genet.2, e40 (2006).

    Google Scholar 

52. Krivtsov, A.V. & Armstrong, S.A. MLL translocations, histone modifications and leukaemia stem-cell development.Nat. Rev. Cancer7, 823–833 (2007).

    Google Scholar 

53. Chi, P., Allis, C.D. & Wang, G.G. Covalent histone modifications—miswritten, misinterpreted and mis-erased in human cancers.Nat. Rev. Cancer10, 457–469 (2010).

    Google Scholar 

54. Hamamoto, R. et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.Nat. Cell Biol.6, 731–740 (2004).

    Google Scholar 

55. Bracken, A.P. & Helin, K. Polycomb group proteins: navigators of lineage pathways led astray in cancer.Nat. Rev. Cancer9, 773–784 (2009).

    Google Scholar 

56. Lu, C. et al. Regulation of tumor angiogenesis by EZH2.Cancer Cell18, 185–197 (2010).

    Google Scholar 

57. Morin, R.D. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.Nat. Genet.42, 181–185 (2010).

    Google Scholar 

58. Berdasco, M. et al. Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma.Proc. Natl. Acad. Sci. USA106, 21830–21835 (2009).

    Google Scholar 

59. Wang, G.G., Cai, L., Pasillas, M.P. & Kamps, M.P. NUP98–NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis.Nat. Cell Biol.9, 804–812 (2007).

    Google Scholar 

60. Herman, J.G. & Baylin, S.B. Gene silencing in cancer in association with promoter hypermethylation.N. Engl. J. Med.349, 2042–2054 (2003).

    Google Scholar 

61. Costello, J.F. et al. Aberrant CpG-island methylation has non-random and tumour-type–specific patterns.Nat. Genet.24, 132–138 (2000).

    Google Scholar 

62. Esteller, M., Corn, P.G., Baylin, S.B. & Herman, J.G. A gene hypermethylation profile of human cancer.Cancer Res.61, 3225–3229 (2001).

    Google Scholar 

63. Laird, P.W. The power and the promise of DNA methylation markers.Nat. Rev. Cancer3, 253–266 (2003).

    Google Scholar 

64. Shivapurkar, N. & Gazdar, A.F. DNA methylation based biomarkers in non-invasive cancer screening.Curr. Mol. Med.10, 123–132 (2010).

    Google Scholar 

65. Esteller, M. et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients.Cancer Res.59, 67–70 (1999).

    Google Scholar 

66. Chen, W.D. et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene.J. Natl. Cancer Inst.97, 1124–1132 (2005).

    Google Scholar 

67. Hoque, M.O. et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.J. Natl. Cancer Inst.98, 996–1004 (2006).

    Google Scholar 

68. Belinsky, S.A. et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort.Cancer Res.66, 3338–3344 (2006).

    Google Scholar 

69. Bailey, V.J. et al. MS-qFRET: a quantum dot-based method for analysis of DNA methylation.Genome Res.19, 1455–1461 (2009).

    Google Scholar 

70. Li, M. et al. Sensitive digital quantification of DNA methylation in clinical samples.Nat. Biotechnol.27, 858–863 (2009).

    Google Scholar 

71. Belinsky, S.A. Gene-promoter hypermethylation as a biomarker in lung cancer.Nat. Rev. Cancer4, 707–717 (2004).

    Google Scholar 

72. Lee, W.H. et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis.Proc. Natl. Acad. Sci. USA91, 11733–11737 (1994).

    Google Scholar 

73. Esteller, M. et al. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia.Cancer Res.58, 4515–4518 (1998).

    Google Scholar 

74. Brooks, J.D. et al. CG island methylation changes near theGSTP1 gene in prostatic intraepithelial neoplasia.Cancer Epidemiol. Biomarkers Prev.7, 531–536 (1998).

    Google Scholar 

75. Jerónimo, C. et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma.J. Natl. Cancer Inst.93, 1747–1752 (2001).

    Google Scholar 

76. Cairns, P. et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation.Clin. Cancer Res.7, 2727–2730 (2001).

    Google Scholar 

77. Hoque, M.O. et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.J. Clin. Oncol.23, 6569–6575 (2005).

    Google Scholar 

78. Bastian, P.J. et al. CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer.J Urol179, 529–534 (2008).

    Google Scholar 

79. Richiardi, L. et al. Promoter methylation in APC, RUNX3 and GSTP1 and mortality in prostate cancer patients.J. Clin. Oncol.27, 3161–3168 (2009).

    Google Scholar 

80. Weigelt, B., Baehner, F.L. & Reis-Filho, J.S. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade.J. Pathol.220, 263–280 (2010).

    Google Scholar 

81. Hernandez-Vargas, H. et al. Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors.PLoS ONE5, e9749 (2010).

    Google Scholar 

82. Noushmehr, H. et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.Cancer Cell17, 510–522 (2010).

    Google Scholar 

83. Brock, M.V. et al. DNA methylation markers and early recurrence in stage I lung cancer.N. Engl. J. Med.358, 1118–1128 (2008).

    Google Scholar 

84. Lujambio, A. et al. A microRNA DNA methylation signature for human cancer metastasis.Proc. Natl. Acad. Sci. USA105, 13556–13561 (2008).

    Google Scholar 

85. Fernandez, A.F. et al. The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer.Genome Res.19, 438–451 (2009).

    Google Scholar 

86. Esteller, M. et al. Inactivation of the DNA-repair geneMGMT and the clinical response of gliomas to alkylating agents.N. Engl. J. Med.343, 1350–1354 (2000).

    Google Scholar 

87. Hegi, M.E. et al.MGMT gene silencing and benefit from temozolomide in glioblastoma.N. Engl. J. Med.352, 997–1003 (2005).

    Google Scholar 

88. Paz, M.F. et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.Clin. Cancer Res.10, 4933–4938 (2004).

    Google Scholar 

89. Esteller, M., Hamilton, S.R., Burger, P.C., Baylin, S.B. & Herman, J.G. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia.Cancer Res.59, 793–797 (1999).

    Google Scholar 

90. Weller, M. et al.MGMT promoter methylation in malignant gliomas: ready for personalized medicine?Nat. Rev. Neurol.6, 39–51 (2010).

    Google Scholar 

91. Martinez, R. et al. Frequent hypermethylation of the DNA repair geneMGMT in long-term survivors of glioblastoma multiforme.J. Neurooncol.83, 91–93 (2007).

    Google Scholar 

92. Stupp, R. et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.J. Clin. Oncol.28, 2712–2718 (2010).

    Google Scholar 

93. Chakravarti, A. et al. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms.Clin. Cancer Res.12, 4738–4746 (2006).

    Google Scholar 

94. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways.Nature455, 1061–1068 (2008).

95. McCormack, A.I. et al. Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours.Clin. Endocrinol.71, 226–233 (2009).

    Google Scholar 

96. Esteller, M. et al. Hypermethylation of the DNA repair gene O6-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma.J. Natl. Cancer Inst.94, 26–32 (2002).

    Google Scholar 

97. Watson, A.J. et al. Tumor O6-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib.Clin. Cancer Res.16, 743–749 (2010).

    Google Scholar 

98. Plumb, J.A., Strathdee, G., Sludden, J., Kaye, S.B. & Brown, R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.Cancer Res.60, 6039–6044 (2000).

    Google Scholar 

99. Agrelo, R. et al. Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer.Proc. Natl. Acad. Sci. USA103, 8822–8827 (2006).

    Google Scholar 

100. Ibanez de Caceres, I. et al. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.Oncogene29, 1681–1690 (2010).

     Google Scholar 

101. Veeck, J.R.S., Setien, F., Gonzalez-Suarez, E., Osorio, A., Benitez, J., Herman, J.G. & Esteller, M. BRCA1 CpG island hypermethylation predicts sensitivity to poly (adenosine diphosphate)-ribose polymerase inhibitors.J. Clin. Oncol.28, e563–e564 (2010).

     Google Scholar 

102. Koga, Y. et al. The significance of aberrant CHFR methylation for clinical response to microtubule inhibitors in gastric cancer.J. Gastroenterol.41, 133–139 (2006).

     Google Scholar 

103. Toyota, M. et al. Epigenetic inactivation of CHFR in human tumors.Proc. Natl. Acad. Sci. USA100, 7818–7823 (2003).

     Google Scholar 

104. Ferreri, A.J. et al. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas.Br. J. Haematol.126, 657–664 (2004).

     Google Scholar 

105. Dejeux, E. et al. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response.Mol. Cancer9, 68 (2010).

     Google Scholar 

106. Billam, M., Witt, A.E. & Davidson, N.E. The silent estrogen receptor: Can we make it speak?Cancer Biol. Ther.8, 485–496 (2009).

     Google Scholar 

107. Laird, P.W. Principles and challenges of genome-wide DNA methylation analysis.Nat. Rev. Genet.11, 191–203 (2010).

     Google Scholar 

108. Li, M. et al. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer.BMC Med. Genomics2, 34 (2009).

     Google Scholar 

109. Balch, C. et al. Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer.Mol. Cancer Ther.4, 1505–1514 (2005).

     Google Scholar 

110. Byrd, J.C. et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.Blood105, 959–967 (2005).

     Google Scholar 

111. Garcia, J.S., Jain, N. & Godley, L.A. An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes.Onco. Targets Ther.3, 1–13 (2010).

     Google Scholar 

112. O'Connor, O.A. et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.J. Clin. Oncol.24, 166–173 (2006).

     Google Scholar 

113. Piekarz, R.L. et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.J. Clin. Oncol.27, 5410–5417 (2009).

     Google Scholar 

114. Beumer, J.H. et al. Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).Cancer Chemother. Pharmacol.62, 363–368 (2008).

     Google Scholar 

115. Flotho, C. et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells.Leukemia23, 1019–1028 (2009).

     Google Scholar 

116. Fang, M.Z. et al. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines.Cancer Res.63, 7563–7570 (2003).

     Google Scholar 

117. Lee, B.H., Yegnasubramanian, S., Lin, X. & Nelson, W.G. Procainamide is a specific inhibitor of DNA methyltransferase 1.J. Biol. Chem.280, 40749–40756 (2005).

     Google Scholar 

118. Segura-Pacheco, B. et al. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy.Clin. Cancer Res.9, 1596–1603 (2003).

     Google Scholar 

119. Villar-Garea, A., Fraga, M.F., Espada, J. & Esteller, M. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells.Cancer Res.63, 4984–4989 (2003).

     Google Scholar 

120. Siedlecki, P. et al. Discovery of two novel, small-molecule inhibitors of DNA methylation.J. Med. Chem.49, 678–683 (2006).

     Google Scholar 

121. Keppler, B.R. & Archer, T.K. Chromatin-modifying enzymes as therapeutic targets–Part 1.Expert Opin. Ther. Targets12, 1301–1312 (2008).

     Google Scholar 

122. Joseph, J. et al. Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB.Oncogene23, 6304–6315 (2004).

     Google Scholar 

123. Nebbioso, A. et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells.Nat. Med.11, 77–84 (2005).

     Google Scholar 

124. Bedalov, A., Gatbonton, T., Irvine, W.P., Gottschling, D.E. & Simon, J.A. Identification of a small molecule inhibitor of Sir2p.Proc. Natl. Acad. Sci. USA98, 15113–15118 (2001).

     Google Scholar 

125. Bitterman, K.J., Anderson, R.M., Cohen, H.Y., Latorre-Esteves, M. & Sinclair, D.A. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1.J. Biol. Chem.277, 45099–45107 (2002).

     Google Scholar 

126. Grozinger, C.M., Chao, E.D., Blackwell, H.E., Moazed, D. & Schreiber, S.L. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening.J. Biol. Chem.276, 38837–38843 (2001).

     Google Scholar 

127. Ota, H. et al. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells.Oncogene25, 176–185 (2006).

     Google Scholar 

128. Kojima, K. et al. A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells.Biochem. Biophys. Res. Commun.373, 423–428 (2008).

     Google Scholar 

129. Heltweg, B. et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes.Cancer Res.66, 4368–4377 (2006).

     Google Scholar 

130. Lara, E. et al. Salermide, a sirtuin inhibitor with a strong cancer-specific proapoptotic effect.Oncogene28, 781–791 (2009).

     Google Scholar 

131. Lain, S. et al. Discovery,in vivo activity and mechanism of action of a small-molecule p53 activator.Cancer Cell13, 454–463 (2008).

     Google Scholar 

132. Balasubramanyam, K. et al. Curcumin, a novel p300/CREB-binding protein–specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase–dependent chromatin transcription.J. Biol. Chem.279, 51163–51171 (2004).

     Google Scholar 

133. Mukhopadhyay, A. et al. Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation.Oncogene21, 8852–8861 (2002).

     Google Scholar 

134. Shishodia, S., Amin, H.M., Lai, R. & Aggarwal, B.B. Curcumin (diferuloylmethane) inhibits constitutive NF-κB activation, induces G1/S arrest, suppresses proliferation and induces apoptosis in mantle cell lymphoma.Biochem. Pharmacol.70, 700–713 (2005).

     Google Scholar 

135. Shishodia, S., Chaturvedi, M.M. & Aggarwal, B.B. Role of curcumin in cancer therapy.Curr. Probl. Cancer31, 243–305 (2007).

     Google Scholar 

136. Balasubramanyam, K. et al. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression.J. Biol. Chem.279, 33716–33726 (2004).

     Google Scholar 

137. Sun, Y., Jiang, X., Chen, S. & Price, B.D. Inhibition of histone acetyltransferase activity by anacardic acid sensitizes tumor cells to ionizing radiation.FEBS Lett.580, 4353–4356 (2006).

     Google Scholar 

138. Stimson, L. et al. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity.Mol. Cancer Ther.4, 1521–1532 (2005).

     Google Scholar 

139. Greiner, D., Bonaldi, T., Eskeland, R., Roemer, E. & Imhof, A. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3–9.Nat. Chem. Biol.1, 143–145 (2005).

     Google Scholar 

140. Isham, C.R. et al. Chaetocin: a promising new antimyeloma agent within vitro andin vivo activity mediated via imposition of oxidative stress.Blood109, 2579–2588 (2007).

     Google Scholar 

141. Tan, J. et al. Pharmacologic disruption of polycomb-repressive complex 2–mediated gene repression selectively induces apoptosis in cancer cells.Genes Dev.21, 1050–1063 (2007).

     Google Scholar 

142. Cheng, D. et al. Small molecule regulators of protein arginine methyltransferases.J. Biol. Chem.279, 23892–23899 (2004).

     Google Scholar 

143. El Messaoudi, S. et al. Coactivator-associated arginine methyltransferase 1 (CARM1) is a positive regulator of the cyclin E1 gene.Proc. Natl. Acad. Sci. USA103, 13351–13356 (2006).

     Google Scholar 

144. Mai, A. et al. epigenetic multiple ligands: mixed histone/protein methyltransferase, acetyltransferase and class III deacetylase (sirtuin) inhibitors.J. Med. Chem.51, 2279–2290 (2008).

     Google Scholar 

145. Lee, M.G., Wynder, C., Schmidt, D.M., McCafferty, D.G. & Shiekhattar, R. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications.Chem. Biol.13, 563–567 (2006).

     Google Scholar 

146. Dawson, M.A. et al. JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin.Nature461, 819–822 (2009).

     Google Scholar 

147. Dar, A.A., Goff, L.W., Majid, S., Berlin, J. & El-Rifai, W. Aurora kinase inhibitors—rising stars in cancer therapeutics?Mol. Cancer Ther.9, 268–278 (2010).

     Google Scholar 

148. Hirota, T., Lipp, J.J., Toh, B.H. & Peters, J.M. Histone H3 serine 10 phosphorylation by aurora B causes HP1 dissociation from heterochromatin.Nature438, 1176–1180 (2005).

     Google Scholar 

149. den Hollander, J. et al. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state.Blood116, 1498–1505 (2010).

     Google Scholar 

150. Görgün, G. et al. A novel aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.Blood115, 5202–5213 (2010).

     Google Scholar 

151. Steeghs, N. et al. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors.J. Clin. Oncol.27, 5094–5101 (2009).

     Google Scholar 

152. Yu, C. et al. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation.Clin. Cancer Res.13, 1140–1148 (2007).

     Google Scholar 

153. Zhang, B. et al. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate.Cancer Cell17, 427–442 (2010).

     Google Scholar 

154. Sharma, S.V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.Cell141, 69–80 (2010).

     Google Scholar 

155. Kantarjian, H.M. et al. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy.Blood116, 3163–3170 (2010).

     Google Scholar 

156. Kanzaki, M. et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells.Oncol. Rep.17, 761–767 (2007).

     Google Scholar 

157. Yang, X., Lay, F., Han, H. & Jones, P.A. Targeting DNA methylation for epigenetic therapy.Trends Pharmacol. Sci.31, 536–546 (2010).

     Google Scholar 

158. Ma, X., Ezzeldin, H.H. & Diasio, R.B. Histone deacetylase inhibitors: current status and overview of recent clinical trials.Drugs69, 1911–1934 (2009).

     Google Scholar 

159. Geng, L. et al. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of γ-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer.Cancer Res.66, 11298–11304 (2006).

     Google Scholar 

160. Beltran, A. et al. Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors.Oncogene26, 2791–2798 (2007).

     Google Scholar 

161. Marchion, D.C., Bicaku, E., Daud, A.I., Sullivan, D.M. & Munster, P.N.In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates.Mol. Cancer Ther.4, 1993–2000 (2005).

     Google Scholar 

162. Brueckner, B. et al. Delivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases therapeutic drug efficacy.Mol. Cancer Ther.9, 1256–1264 (2010).

     Google Scholar 

163. Li, Y. et al. The DNA methylome of human peripheral blood mononuclear cells.PLoS Biol.8, e1000533 (2010).

     Google Scholar 

164. Gilbert, J. et al. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies.Clin. Cancer Res.7, 2292–2300 (2001).

     Google Scholar 

165. Göttlicher, M. et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.EMBO J.20, 6969–6978 (2001).

     Google Scholar 

166. Terao, Y. et al. Sodium butyrate induces growth arrest and senescence-like phenotypes in gynecologic cancer cells.Int. J. Cancer94, 257–267 (2001).

     Google Scholar 

167. Chen, S., Ye, J., Kijima, I. & Evans, D. The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression.Proc. Natl. Acad. Sci. USA107, 11032–11037 (2010).

     Google Scholar 

168. Khan, N. et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.Biochem. J.409, 581–589 (2008).

     Google Scholar 

169. Qian, X. et al. Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer.Int. J. Cancer122, 1400–1410 (2008).

     Google Scholar 

170. Steele, N.L. et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors.Clin. Cancer Res.14, 804–810 (2008).

     Google Scholar 

171. Itoh, Y., Suzuki, T. & Miyata, N. Isoform-selective histone deacetylase inhibitors.Curr. Pharm. Des.14, 529–544 (2008).

     Google Scholar 

172. Fournel, M. et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activityin vitro andin vivo.Mol. Cancer Ther.7, 759–768 (2008).

     Google Scholar 

173. Hess-Stumpp, H., Bracker, T.U., Henderson, D. & Politz, O. MS-275, a potent orally available inhibitor of histone deacetylases—the development of an anticancer agent.Int. J. Biochem. Cell Biol.39, 1388–1405 (2007).

     Google Scholar 

174. Lucas, D.M. et al. The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells.Leukemia18, 1207–1214 (2004).

     Google Scholar 

Download references